138 related articles for article (PubMed ID: 6978743)
1. Emergence of B-immunoblastic sarcoma in patients with multiple myeloma: a clinicopathologic study of 10 cases.
Falini B; De Solas I; Levine AM; Parker JW; Lukes RJ; Taylor CR
Blood; 1982 May; 59(5):923-33. PubMed ID: 6978743
[TBL] [Abstract][Full Text] [Related]
2. Malignant B cell immunoblastic lymphoma expressing CD30 antigen in the terminal phase of a multiple myeloma.
Castrillo JM; Rivas C; Alonso C; Varela A; Gonzalo A; Jimenéz-Casado M
Appl Pathol; 1989; 7(6):375-81. PubMed ID: 2561814
[TBL] [Abstract][Full Text] [Related]
3. Sequential maturation stages of monoclonal B lineage cells from blood, spleen, lymph node, and bone marrow from a terminal myeloma patient.
Jensen GS; Mant MJ; Pilarski LM
Am J Hematol; 1992 Nov; 41(3):199-208. PubMed ID: 1384318
[TBL] [Abstract][Full Text] [Related]
4. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens.
Costes V; Magen V; Legouffe E; Durand L; Baldet P; Rossi JF; Klein B; Brochier J
Hum Pathol; 1999 Dec; 30(12):1405-11. PubMed ID: 10667416
[TBL] [Abstract][Full Text] [Related]
5. Bilateral extramedullary plasmacytomas of the palatine tonsils: a case report.
Hanna EY; Lavertu P; Tucker HM; Tubbs RP
Otolaryngol Head Neck Surg; 1990 Dec; 103(6):1024-7. PubMed ID: 2126117
[No Abstract] [Full Text] [Related]
6. Immunophenotypic differences between plasmacytoma/multiple myeloma and immunoblastic lymphoma.
Strickler JG; Audeh MW; Copenhaver CM; Warnke RA
Cancer; 1988 May; 61(9):1782-6. PubMed ID: 3355976
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
Conlan MG; Bast M; Armitage JO; Weisenburger DD
J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
[TBL] [Abstract][Full Text] [Related]
8. [Research Progress on Multiple Myeloma with Extramedullary Disease].
Wang L; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):945-8. PubMed ID: 27342539
[TBL] [Abstract][Full Text] [Related]
9. [Anaplastic myeloma and immunoblastic lymphoma: a comparison].
Banks PM; Strand WR; Kyle RA
Verh Dtsch Ges Pathol; 1983; 67():447-50. PubMed ID: 6666273
[No Abstract] [Full Text] [Related]
10. Immunoblastic lymphadenopathy. Evolution into a malignant lymphoma with plasmacytoid features.
Fisher RI; Jaffe ES; Braylan RC; Andersen JC; Tan HK
Am J Med; 1976 Oct; 61(4):553-9. PubMed ID: 973649
[TBL] [Abstract][Full Text] [Related]
11. Neoplasms of terminally differentiated B lymphocytes.
Holbert JM
Clin Lab Med; 1988 Mar; 8(1):197-210. PubMed ID: 3282759
[TBL] [Abstract][Full Text] [Related]
12. [Detection of circulating and bone marrow myeloma cells in patients with multiple myeloma and its clinical significance].
Jiang YQ; Li JY; Wu YJ; Yang H; Shen YF; Chen LJ; Xu W; Qian SX; Wu HX; Lu H; Shen RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):908-12. PubMed ID: 17096887
[TBL] [Abstract][Full Text] [Related]
13. Evidence for the existence of circulating monoclonal B-lymphocytes in multiple myeloma patients.
Cassel A; Leibovitz N; Hornstein L; Quitt M; Aghai E
Exp Hematol; 1990 Dec; 18(11):1171-3. PubMed ID: 2226677
[TBL] [Abstract][Full Text] [Related]
14. [Immunocytologic diagnosis of leukemia and lymphoma: monoclonal antibodies in the differential diagnosis of hematologic neoplasms].
Huber H; Gattringer C; Thaler J; Peschel C
Behring Inst Mitt; 1985 Dec; (78):83-117. PubMed ID: 3914283
[TBL] [Abstract][Full Text] [Related]
15. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
[TBL] [Abstract][Full Text] [Related]
16. Anaplastic plasma cell myeloma and immunoblastic lymphoma. Clinical, pathologic, and immunologic comparison.
Strand WR; Banks PM; Kyle RA
Am J Med; 1984 May; 76(5):861-7. PubMed ID: 6547021
[TBL] [Abstract][Full Text] [Related]
17. Evidence of prolactin immunoreactivity in the bone marrow of untreated multiple myeloma patients.
Gadó K; Nagy G; Hasitz A; Tóth BE; Rimanóczi E; Domján G
Neuroimmunomodulation; 2001; 9(2):95-102. PubMed ID: 11549891
[TBL] [Abstract][Full Text] [Related]
18. Morphologic heterogeneity and plasmablastic transformation in advanced plasmacytic/plasmablastic myeloma: a study of 35 serial bone marrow biopsies in 9 patients.
Paule B; Quillard J; Bennet P; Mariette X; Bisson M
Nouv Rev Fr Hematol (1978); 1989; 31(3):203-8. PubMed ID: 2616267
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma: 'early' plasma cell phenotype identifies patients with aggressive biological and clinical characteristics.
Omedè P; Boccadoro M; Fusaro A; Gallone G; Pileri A
Br J Haematol; 1993 Nov; 85(3):504-13. PubMed ID: 8136273
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma.
Anderson KC; Barut BA; Ritz J; Freedman AS; Takvorian T; Rabinowe SN; Soiffer R; Heflin L; Coral F; Dear K
Blood; 1991 Feb; 77(4):712-20. PubMed ID: 1993214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
